PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (Nasdaq:ARWR) announced today a fundamental streamlining of its majority-owned subsidiaries, Calando Pharmaceuticals and Insert Therapeutics. Arrowhead will assume active management of the companies and focus resources on bringing multiple products to the clinic as rapidly as possible. Arrowhead’s expanded role is intended to make Calando and Insert operations more efficient. This is a process that includes a merger of the companies, which has been submitted to shareholders. Larry Stambaugh has stepped down from his role as CEO of both companies but will remain a consultant to help establish partnerships with larger pharmaceutical companies.
